GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Xinhua Pharmaceutical Co Ltd (HKSE:00719) » Definitions » Research & Development

Shandong Xinhua Pharmaceutical Co (HKSE:00719) Research & Development : HK$488 Mil (TTM As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Shandong Xinhua Pharmaceutical Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Shandong Xinhua Pharmaceutical Co's Research & Development for the three months ended in Mar. 2024 was HK$154 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was HK$488 Mil.


Shandong Xinhua Pharmaceutical Co Research & Development Historical Data

The historical data trend for Shandong Xinhua Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Xinhua Pharmaceutical Co Research & Development Chart

Shandong Xinhua Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 261.94 353.67 417.99 386.00 458.56

Shandong Xinhua Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 127.70 134.98 113.44 85.27 154.15

Shandong Xinhua Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$488 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shandong Xinhua Pharmaceutical Co  (HKSE:00719) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Shandong Xinhua Pharmaceutical Co Research & Development Related Terms

Thank you for viewing the detailed overview of Shandong Xinhua Pharmaceutical Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Xinhua Pharmaceutical Co (HKSE:00719) Business Description

Traded in Other Exchanges
Address
No. 1 Lutai Avenue, Hi-tech Industry Development Zone, Zibo City, Shandong, CHN, 255086
Shandong Xinhua Pharmaceutical Co Ltd is a pharmaceutical products manufacturer based in China. It operates the business through the following segments: Chemical bulk drugs, Preparations, Chemical intermediates, and other products. The company provides chemical bulk drug products, including metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, and L-dopa, it also dispenses formulation products such as compound liquorice tablets and nimodipine tablets. Its products address disorders related to the central nervous system and the cerebrovascular system with the help of antipyretics and analgesics.

Shandong Xinhua Pharmaceutical Co (HKSE:00719) Headlines

No Headlines